Search results for " pulmonary"

showing 10 items of 517 documents

Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA.

2019

Extracellular vesicles are released by numerous cell types of the human body under physiological but also under pathophysiological conditions. They are important for cell&ndash

0301 basic medicineMalemedicine.drug_classHypertension Pulmonarylcsh:QR1-502Piwi-interacting RNA030204 cardiovascular system & hematologyBiologyBiochemistrylcsh:MicrobiologyArticlechronic thromboembolic pulmonary hypertension03 medical and health sciencesExtracellular Vesicles0302 clinical medicinemicroRNAmedicineNatriuretic peptideHumansMolecular BiologyAgedsmall non-coding RNApulmonary diseaseExtracellular vesicleMiddle Agedmedicine.diseaseNon-coding RNAPulmonary hypertensionCell biology030104 developmental biologymedicine.anatomical_structureCase-Control StudiesVascular resistanceBiomarker (medicine)RNA Small UntranslatedbiomarkerFemaleextracellular vesiclesright heart dysfunctionBiomolecules
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct

Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with…

2020

Contains fulltext : 229471.pdf (Publisher’s version ) (Closed access) OBJECTIVES: To summarize the available evidence on the diagnostic performance for invasive aspergillosis (IA) in non-hematological, non-solid organ transplantation critically ill patients of the following: (i) existing definitions of IA (developed either for classical immunocompromised populations or for non-immunocompromised critically ill patients); (ii) laboratory tests; (iii) radiology tests. METHODS: A systematic review was performed by evaluating studies assessing the diagnostic performance for IA of a definition/s and/or laboratory/radiology test/s vs. a reference standard (histology) or a reference definition. RES…

0301 basic medicineMicrobiology (medical)Adultmedicine.medical_specialtyCritical Illness030106 microbiologyAspergillosisSensitivity and SpecificityOrgan transplantationMannans03 medical and health sciencesGalactomannanchemistry.chemical_compound0302 clinical medicineDiagnosisMedicineHumansAspergillosis030212 general & internal medicineIntensive care medicineInvasive Pulmonary AspergillosisAdult patientsmedicine.diagnostic_testbusiness.industryCritically illIABiomarkerInvasive pulmonary aspergillosismedicine.diseaseAspergillulnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesBronchoalveolar lavageAspergilluschemistryIPAAspergillus; Biomarker; Diagnosis; IA; IPA; Invasive aspergillosis; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisBiomarker (medicine)Aspergillus; Biomarker; Diagnosis; IA; Invasive aspergillosis; IPA; Adult; Bronchoalveolar Lavage Fluid; Critical Illness; Humans; Mannans; Sensitivity and Specificity; Aspergillosis; Invasive Pulmonary AspergillosisInvasive aspergillosisbusinessBronchoalveolar Lavage FluidDiagnosi
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct

Clinical and Imaging Features of Adults with Recurrent Pulmonary Tuberculosis - A Prospective Case-Controlled Study

2021

Background: Recurrent pulmonary tuberculosis (RPTB) is a growing, important and neglected problem affecting treated TB patients and TB health services across the world, particularly in sub-Saharan Africa. Analyses and identification of differences in clinical features between recurrent PTB and newly diagnosed PTB may lead to improved management recommendations. Methods: Between September 1st 2019 and January 31st 2020, we performed a prospective case controlled study of clinical and imaging features of patients with recurrent pulmonary tuberculosis and compared them with those of newly diagnosed PTB cases. Recurrent PTB was defined as a patient with bacteriologically confirmed active PTB wh…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty030106 microbiologyInfectious and parasitic diseasesRC109-216Lung injuryChest painLogistic regressionImagingClinical03 medical and health sciences0302 clinical medicinePulmonary tuberculosisInternal medicineHumansMedicine030212 general & internal medicineTuberculosis PulmonaryLung functionLungbusiness.industryAssociated factorsPulmonary tuberculosisCase-control studyGeneral MedicineInfectious Diseasesmedicine.anatomical_structureRadiological weaponmedicine.symptomRecurrentbusinessInternational Journal of Infectious Diseases
researchProduct

Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis

2019

Abstract Neutrophil extracellular traps (NETs) are formed by polymorphonuclear neutrophils (PMN) and contribute to the innate host defense by binding and killing bacterial and fungal pathogens. Because NET formation depends on histone hypercitrullination by peptidylarginine deiminase 4 (PAD4), we used PAD4 gene deficient (Pad4-/-) mice in a mouse model of invasive pulmonary aspergillosis (IPA) to address the contribution of NETs to the innate host defense in vivo. After the induction (24 h) of IPA by i.t. infection with Aspergillus fumigatus conidia, Pad4-/- mice revealed lower fungal burden in the lungs, accompanied by less acute lung injury, TNFα and citH3 compared to wildtype controls. T…

0301 basic medicineNeutrophilsImmunologyMedizinApoptosisLung injuryExtracellular TrapsArticleAspergillus fumigatusMicrobiologyMice03 medical and health sciences0302 clinical medicineProtein-Arginine Deiminase Type 4In vivomedicineAnimalsHumansImmunology and Allergyskin and connective tissue diseasesLungInvasive Pulmonary AspergillosisMice KnockoutLungbiologyAspergillus fumigatusWild typeHematologyNeutrophil extracellular trapsbiology.organism_classificationmedicine.diseaseImmunity Innaterespiratory tract diseasesMice Inbred C57BLDisease Models AnimalPneumonia030104 developmental biologymedicine.anatomical_structureCitrullinationTumor necrosis factor alpha030215 immunologyImmunobiology
researchProduct

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

2019

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterat…

0301 basic medicineOncologyIndolesLung Neoplasmsnon-small cell lung cancer (NSCLC)Reviewlcsh:Chemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosis0302 clinical medicineCarcinoma Non-Small-Cell LungMyofibroblastslcsh:QH301-705.5SpectroscopyGeneral MedicinePirfenidonerespiratory systemComputer Science Applicationsnon-small cell lung cancer (NSCLC)030220 oncology & carcinogenesisNintedanibidiopathic pulmonary fibrosis (IPF)Myofibroblastmedicine.drugmedicine.medical_specialtyPyridonesAntineoplastic AgentsCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicineAnimalsHumansPhysical and Theoretical ChemistryLung cancerMolecular Biologylung cancer (LC)business.industryOrganic ChemistryMesenchymal stem cellmedicine.diseaseIdiopathic Pulmonary Fibrosisrespiratory tract diseases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryConcomitantbusinessInternational Journal of Molecular Sciences
researchProduct

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

2017

Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology. Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled in the study between September 2007 and September 2015. All o…

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyBevacizumabmedicine.medical_treatmentSquamous-NSCLC (sqNSCLC)03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalRadical surgeryEtoposideEtoposideChemotherapybusiness.industryMetronomic chemotherapyCancermedicine.diseaseMetronomic ChemotherapyBevacizumabRegimen030104 developmental biology030220 oncology & carcinogenesisOriginal ArticleCisplatinbusinessBevacizumab; Cisplatin; Etoposide; Metronomic chemotherapy; Squamous-NSCLC (sqNSCLC); Pulmonary and Respiratory Medicinemedicine.drug
researchProduct

Exosomes in lung cancer liquid biopsies: Two sides of the same coin?

2017

LETTER TO EDITOR

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyCancer ResearchLung NeoplasmsMEDLINEExosomes03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorHumansLiquid biopsyLung cancerbusiness.industryLiquid Biopsymedicine.diseaseMicrovesicles030104 developmental biologyOncology030220 oncology & carcinogenesisHuman medicinebusinessOncology; Pulmonary and Respiratory Medicine; Cancer Research
researchProduct

Oxidative Stress and Endoplasmic Reticulum Stress in Rare Respiratory Diseases

2021

Several studies have shown that some rare respiratory diseases, such as alpha-1 antitrypsin deficiency (AATD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), and primary ciliary dyskinesia (PCD) present oxidative stress (OS) and endoplasmic reticulum (ER) stress. Their involvement in these pathologies and the use of antioxidants as therapeutic agents to minimize the effects of OS are discussed in this review.

0301 basic medicinePathologymedicine.medical_specialtylcsh:Medicineprimary ciliary dyskinesiaReviewrare respiratory diseasesmedicine.disease_causeCystic fibrosiscystic fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineotorhinolaryngologic diseasesmedicineoxidative stressRespiratory systemPrimary ciliary dyskinesiaAlpha 1-antitrypsin deficiencybusiness.industryEndoplasmic reticulumlcsh:RGeneral Medicineidiopathic pulmonary fibrosismedicine.diseaserespiratory tract diseases030104 developmental biologyAlpha-1 antitrypsin deficiency030220 oncology & carcinogenesisendoplasmic reticulum stressantioxidant therapiesbusinessOxidative stressJournal of Clinical Medicine
researchProduct